<--- Back to Details
First PageDocument Content
Pharmacology / Gilead Sciences / Organofluorides / Cyclopropanes / Bristol-Myers Squibb / Reverse-transcriptase inhibitor / Fixed-dose combination / Emtricitabine / Lamivudine / Fixed dose combination / Chemistry / Organic chemistry
Date: 2014-01-07 15:28:36
Pharmacology
Gilead Sciences
Organofluorides
Cyclopropanes
Bristol-Myers Squibb
Reverse-transcriptase inhibitor
Fixed-dose combination
Emtricitabine
Lamivudine
Fixed dose combination
Chemistry
Organic chemistry

AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 470 COMBINATION MEDICATIONS

Add to Reading List

Source URL: www.aidsinfonet.org

Download Document from Source Website

File Size: 57,00 KB

Share Document on Facebook

Similar Documents

DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE

DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE

DocID: 1pw8Q - View Document

Human Immunodeficiency Virus (HIV) is a potential precursor to Acquired Immune Deficiency Syndrome (AIDS), which commonly treated with a mixture of reverse transcriptase inhibitors (RTI) and protease inhibitors (PI). Ada

Human Immunodeficiency Virus (HIV) is a potential precursor to Acquired Immune Deficiency Syndrome (AIDS), which commonly treated with a mixture of reverse transcriptase inhibitors (RTI) and protease inhibitors (PI). Ada

DocID: 1pbRe - View Document

New Zealand Consumer Medicine Information  Viramune Tablets and Oral Suspension Nevirapine

New Zealand Consumer Medicine Information Viramune Tablets and Oral Suspension Nevirapine

DocID: 1gvCL - View Document

Viramune Tablets Viramune Oral Suspension Nevirapine Consumer Medicine Information

Viramune Tablets Viramune Oral Suspension Nevirapine Consumer Medicine Information

DocID: 1gtrY - View Document

ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL

ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL

DocID: 1fNy0 - View Document